news
-
MU2net Unity: 1st Product Release
- October 7, 2019
Supporting adaptive workflows, MU2net releases its first version 2.1.1.7 compatible with Elekta Unity (MLC-Y) to perform secondary independent dose calculation.
-
EANM ANNUAL CONGRESS 2019
- September 16, 2019
Annual Congress of the European Association of Nuclear Medicine (EANM)
October 12-16, 2019
CCIB – Centre de Convencions Internacional de Barcelona, Spain
Booth #109 -
APMP Seminar 2019
- September 10, 2019
October 12, 2019
Hôtel Mélia Paris La Défense, France -
[AuntMinnie.com] Elekta, DOSIsoft sign distribution agreement
- September 6, 2019
Radiation oncology vendor Elekta has signed a distribution agreement with radiation oncology and nuclear medicine software developer DOSIsoft.
-
[Elekta’s PR] Elekta announces Exclusive Agreement with DOSIsoft for Distribution of Key Patient Specific QA Solutions
- September 5, 2019
Products fill out company’s Elekta Assurance portfolio for comprehensive end-to-end quality assurance.
-
CIO 2019
- September 1, 2019
Annual Symposium on Clinical Interventional Oncology (CIO)
October 11-13, 2019
Eden Roc Miami Beach, Miami Beach, USA -
[Article] Analysis of Differences Between 99mTc-MAASPECT- and 90Y-microsphere PET-based Dosimetry for Hepatocellular Carcinoma Selective Internal Radiation Therapy
- July 22, 2019
Marilyne Kafrouni, Carole Allimant, Marjolaine Fourcade, Sébastien Vauclin, et al.
EJNMMI Res (2019) 9: 62. https://doi.org/10.1186/s13550-019-0533-6 -
ASTRO ANNUAL MEETING 2019
- June 27, 2019
The American Society for Radiation & Oncology (ASTRO) Annual Meeting
September 15-18, 2019
McCormick Place West, Chicago, IL
Booth #4420 -
QA customer centers in expansion worldwide
- June 26, 2019
An increasing number of RT hospital centers in the world have adopted DOSIsoft’s Patient Quality Assurance (QA) software to optimize their patient QA processus and improve patient safety.
-
[HCB News] Software Innovations for Patient-specific Theranostics and Molecular Radiotherapy
- June 25, 2019
Molecular radiotherapy (MRT) is a promising and quickly expanding set of therapeutic options for treating many cancer cases, including cases where conventional techniques are unsuccessful. Cancer cases have been treated with radiopharmaceuticals since the 1940s, but the number and range of radiotherapeutics on the market have recently expanded significantly. Discover how software technologies innovate Theranostics and Molecular Radiotherapy in a patient-specific approach.